查看文章

There are limited data on treatment effect in early and drug‐naïve Parkinson's disease (PD) outside of clinical trials. We sought to review the treatment effects on motor symptoms in early, unselected PD patients.

We included 183 drug‐naïve patients from a longitudinal cohort (The Norwegian ParkWest study). At the time of diagnosis, motor symptoms were assessed and rated. Treatment was unrestricted, aimed at treating each patient optimally. Patients were reassessed after 12 months, and then grouped according to treatment: No dopaminergic treatment (NDT), dopamine agonists (DA) or levodopa. All strategies could be combined with monoamine oxidase B inhibitors.

In general, the chosen treatment was coherent with current practice. During follow‐up, patients given NDT (n = 40) had unaltered clinical motor symptoms, as opposed to improvement in the DA‐ and levodopa‐treated …